Monopar Therapeutics Closes $19.2M Public Stock Offering

Monopar Therapeutics Inc., a clinical-stage biotechnology company based in Wilmette, Illinois, has officially concluded its public offering of common stock, which was priced at $16.25 per share. This move has generated gross proceeds of approximately $19.2 million, prior to the subtraction of fees and other expenses related to the offering.

The funding round saw participation from significant investors in the growth and life sciences sectors, including Janus Henderson Investors and RA Capital Management, L.P. The exclusive placement agent for this offering was Rodman & Renshaw LLC. Monopar Therapeutics has earmarked the net proceeds from this public offering for a variety of general corporate purposes. These include expenses related to research and development, clinical trials, manufacturing, supply chain needs, and working capital.

The shares were offered and sold under a "shelf" registration statement on Form S-3 (File No. 333-268935), which was initially filed with the U.S. Securities and Exchange Commission (SEC) on December 21, 2022, and became effective on January 4, 2023. 

Monopar Therapeutics, listed on Nasdaq under the ticker MNPR, focuses on developing innovative treatments for patients with unmet medical needs. The company's pipeline includes late-stage ALXN-1840 for the treatment of Wilson disease, and radiopharmaceutical initiatives, such as the Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1a-stage MNPR-101-Lu, and the late preclinical-stage MNPR-101-Ac225 for treating advanced cancers. 

Rodman & Renshaw LLC managed the offering, offering copies of the final prospectus supplement and the accompanying prospectus for those interested, with detailed contact information available for further inquiries.

This announcement clarifies that it is neither an offer to sell nor a solicitation to buy any of the securities described, and no sale of these securities will occur in any jurisdiction where such an offer or sale would be illegal before registration or qualification under the securities laws of that jurisdiction. The offering was conducted exclusively using the prospectus supplement and the accompanying prospectus that formed part of the effective registration statement.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!